GSK severe asthma drug progresses to Phase III - InPharm

GSK severe asthma drug progresses to Phase III
InPharm
The Phase IIb DREAM study was testing mepolizumab in patients with severe eosinophilic asthma, a condition where organs are damaged by the over-production of white blood cells. The year-long study, which involved 621 patients, found the number of …
GSK asthma drug cuts symptoms 52%; ready for PhIIIPharma Times
GSK drug halves attacks in hard-to-treat asthmaBusiness Recorder (blog)
Drug 'could cut asthma A&E visits'World First Travel Insurance
The Inquisitr –Zenopa
all 6 news articles »

GSK severe asthma drug progresses to Phase III – InPharm